MSPrecise

A molecular diagnostic test for multiple sclerosis using next generation sequencing

William H. Rounds, Edward A. Salinas, Tom B. Wilks, Mikhail K. Levin, Ann J. Ligocki, Carolina Ionete, Carlos A Pardo-Villamizar, Steven Vernino, Benjamin M. Greenberg, Douglas W. Bigwood, Eric M. Eastman, Lindsay G. Cowell, Nancy L. Monson

Research output: Contribution to journalArticle

Abstract

Background: We have previously demonstrated that cerebrospinal fluid-derived B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations. These mutations can be quantified as a score that identifies such patients as having or likely to convert to RRMS. Furthermore, we showed that next generation sequencing is an efficient method for obtaining the sequencing information required by this mutation scoring tool, originally developed using the less clinically viable single-cell Sanger sequencing. Objective: To determine the accuracy of MSPrecise, the diagnostic test that identifies the presence of the RRMS-enriched mutation pattern from patient cerebrospinal fluid B cells. Methods: Cerebrospinal fluid cell pellets were obtained from RRMS and other neurological disease (OND) patient cohorts. VH4 gene segments were amplified, sequenced by next generation sequencing and analyzed for mutation score. Results: The diagnostic test showed a sensitivity of 75% on the RRMS cohort and a specificity of 88% on the OND cohort. The accuracy of the test in identifying RRMS patients or patients that will develop RRMS is 84%. Conclusion: MSPrecise exhibits good performance in identifying patients with RRMS irrespective of time with RRMS.

Original languageEnglish (US)
Pages (from-to)191-197
Number of pages7
JournalGene
Volume572
Issue number2
DOIs
StatePublished - Nov 10 2015

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Molecular Pathology
Routine Diagnostic Tests
Multiple Sclerosis
Mutation
Cerebrospinal Fluid
B-Lymphocytes
Genes

Keywords

  • B cell
  • Biomarker
  • Genetics
  • High-throughput nucleotide sequencing
  • Multiple sclerosis
  • Neurological disease

ASJC Scopus subject areas

  • Genetics

Cite this

Rounds, W. H., Salinas, E. A., Wilks, T. B., Levin, M. K., Ligocki, A. J., Ionete, C., ... Monson, N. L. (2015). MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. Gene, 572(2), 191-197. https://doi.org/10.1016/j.gene.2015.07.011

MSPrecise : A molecular diagnostic test for multiple sclerosis using next generation sequencing. / Rounds, William H.; Salinas, Edward A.; Wilks, Tom B.; Levin, Mikhail K.; Ligocki, Ann J.; Ionete, Carolina; Pardo-Villamizar, Carlos A; Vernino, Steven; Greenberg, Benjamin M.; Bigwood, Douglas W.; Eastman, Eric M.; Cowell, Lindsay G.; Monson, Nancy L.

In: Gene, Vol. 572, No. 2, 10.11.2015, p. 191-197.

Research output: Contribution to journalArticle

Rounds, WH, Salinas, EA, Wilks, TB, Levin, MK, Ligocki, AJ, Ionete, C, Pardo-Villamizar, CA, Vernino, S, Greenberg, BM, Bigwood, DW, Eastman, EM, Cowell, LG & Monson, NL 2015, 'MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing', Gene, vol. 572, no. 2, pp. 191-197. https://doi.org/10.1016/j.gene.2015.07.011
Rounds WH, Salinas EA, Wilks TB, Levin MK, Ligocki AJ, Ionete C et al. MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. Gene. 2015 Nov 10;572(2):191-197. https://doi.org/10.1016/j.gene.2015.07.011
Rounds, William H. ; Salinas, Edward A. ; Wilks, Tom B. ; Levin, Mikhail K. ; Ligocki, Ann J. ; Ionete, Carolina ; Pardo-Villamizar, Carlos A ; Vernino, Steven ; Greenberg, Benjamin M. ; Bigwood, Douglas W. ; Eastman, Eric M. ; Cowell, Lindsay G. ; Monson, Nancy L. / MSPrecise : A molecular diagnostic test for multiple sclerosis using next generation sequencing. In: Gene. 2015 ; Vol. 572, No. 2. pp. 191-197.
@article{1a688ad1ae2140e295cad93101874e06,
title = "MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing",
abstract = "Background: We have previously demonstrated that cerebrospinal fluid-derived B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations. These mutations can be quantified as a score that identifies such patients as having or likely to convert to RRMS. Furthermore, we showed that next generation sequencing is an efficient method for obtaining the sequencing information required by this mutation scoring tool, originally developed using the less clinically viable single-cell Sanger sequencing. Objective: To determine the accuracy of MSPrecise, the diagnostic test that identifies the presence of the RRMS-enriched mutation pattern from patient cerebrospinal fluid B cells. Methods: Cerebrospinal fluid cell pellets were obtained from RRMS and other neurological disease (OND) patient cohorts. VH4 gene segments were amplified, sequenced by next generation sequencing and analyzed for mutation score. Results: The diagnostic test showed a sensitivity of 75{\%} on the RRMS cohort and a specificity of 88{\%} on the OND cohort. The accuracy of the test in identifying RRMS patients or patients that will develop RRMS is 84{\%}. Conclusion: MSPrecise exhibits good performance in identifying patients with RRMS irrespective of time with RRMS.",
keywords = "B cell, Biomarker, Genetics, High-throughput nucleotide sequencing, Multiple sclerosis, Neurological disease",
author = "Rounds, {William H.} and Salinas, {Edward A.} and Wilks, {Tom B.} and Levin, {Mikhail K.} and Ligocki, {Ann J.} and Carolina Ionete and Pardo-Villamizar, {Carlos A} and Steven Vernino and Greenberg, {Benjamin M.} and Bigwood, {Douglas W.} and Eastman, {Eric M.} and Cowell, {Lindsay G.} and Monson, {Nancy L.}",
year = "2015",
month = "11",
day = "10",
doi = "10.1016/j.gene.2015.07.011",
language = "English (US)",
volume = "572",
pages = "191--197",
journal = "Gene",
issn = "0378-1119",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - MSPrecise

T2 - A molecular diagnostic test for multiple sclerosis using next generation sequencing

AU - Rounds, William H.

AU - Salinas, Edward A.

AU - Wilks, Tom B.

AU - Levin, Mikhail K.

AU - Ligocki, Ann J.

AU - Ionete, Carolina

AU - Pardo-Villamizar, Carlos A

AU - Vernino, Steven

AU - Greenberg, Benjamin M.

AU - Bigwood, Douglas W.

AU - Eastman, Eric M.

AU - Cowell, Lindsay G.

AU - Monson, Nancy L.

PY - 2015/11/10

Y1 - 2015/11/10

N2 - Background: We have previously demonstrated that cerebrospinal fluid-derived B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations. These mutations can be quantified as a score that identifies such patients as having or likely to convert to RRMS. Furthermore, we showed that next generation sequencing is an efficient method for obtaining the sequencing information required by this mutation scoring tool, originally developed using the less clinically viable single-cell Sanger sequencing. Objective: To determine the accuracy of MSPrecise, the diagnostic test that identifies the presence of the RRMS-enriched mutation pattern from patient cerebrospinal fluid B cells. Methods: Cerebrospinal fluid cell pellets were obtained from RRMS and other neurological disease (OND) patient cohorts. VH4 gene segments were amplified, sequenced by next generation sequencing and analyzed for mutation score. Results: The diagnostic test showed a sensitivity of 75% on the RRMS cohort and a specificity of 88% on the OND cohort. The accuracy of the test in identifying RRMS patients or patients that will develop RRMS is 84%. Conclusion: MSPrecise exhibits good performance in identifying patients with RRMS irrespective of time with RRMS.

AB - Background: We have previously demonstrated that cerebrospinal fluid-derived B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations. These mutations can be quantified as a score that identifies such patients as having or likely to convert to RRMS. Furthermore, we showed that next generation sequencing is an efficient method for obtaining the sequencing information required by this mutation scoring tool, originally developed using the less clinically viable single-cell Sanger sequencing. Objective: To determine the accuracy of MSPrecise, the diagnostic test that identifies the presence of the RRMS-enriched mutation pattern from patient cerebrospinal fluid B cells. Methods: Cerebrospinal fluid cell pellets were obtained from RRMS and other neurological disease (OND) patient cohorts. VH4 gene segments were amplified, sequenced by next generation sequencing and analyzed for mutation score. Results: The diagnostic test showed a sensitivity of 75% on the RRMS cohort and a specificity of 88% on the OND cohort. The accuracy of the test in identifying RRMS patients or patients that will develop RRMS is 84%. Conclusion: MSPrecise exhibits good performance in identifying patients with RRMS irrespective of time with RRMS.

KW - B cell

KW - Biomarker

KW - Genetics

KW - High-throughput nucleotide sequencing

KW - Multiple sclerosis

KW - Neurological disease

UR - http://www.scopus.com/inward/record.url?scp=84941599121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941599121&partnerID=8YFLogxK

U2 - 10.1016/j.gene.2015.07.011

DO - 10.1016/j.gene.2015.07.011

M3 - Article

VL - 572

SP - 191

EP - 197

JO - Gene

JF - Gene

SN - 0378-1119

IS - 2

ER -